Evidence map›Paper›PMID 40255872›Full record

ReviewLiver cancer2025

Particle Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study, Systematic Review and Meta-Analysis.

Masashi Mizumoto, Kei Shibuya, Kazuki Terashima, Masao Murakami, Motohiro Murakami, Yoshiyuki Shioyama, Yoshiro Matsuo, Takashi Ogino, Tatsuya Ohno, Takahiro Waki and 14 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Liver cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Masashi MizumotoDepartment of Radiation Oncology, University of Tsukuba, Tsukuba, Japan.
Kei ShibuyaDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Kazuki TerashimaDepartment of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan.
Masao MurakamiDepartment of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
Motohiro MurakamiDepartment of Radiation Oncology, University of Tsukuba, Tsukuba, Japan.
Yoshiyuki ShioyamaIon Beam Therapy Center, SAGA HIMAT Foundation, Tosu, Japan.
Yoshiro MatsuoDepartment of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan.
Takashi OginoMedipolis Proton Therapy and Research Center, Ibusuki, Japan.
Tatsuya OhnoDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Takahiro WakiDepartment of Radiology, Tsuyama Chuo Hospital, Tsuyama, Japan.
Hiroyuki OginoDepartment of Radiation Oncology, Nagoya City University West Medical Center, Nagoya, Japan.
Hiroyasu TamamuraProton Therapy Center, Fukui Prefectural Hospital, Fukui, Japan.
Norio KatohDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Masaru WakatsukiQST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Tomoaki OkimotoDepartment of Radiology, Hyogo Ion Beam Medical Center, Tatsuno, Japan.
Motohisa SuzukiDepartment of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama, Japan.
Takashi SaitoDepartment of Radiation Oncology, University of Tsukuba, Tsukuba, Japan.
Shingo ToyamaIon Beam Therapy Center, SAGA HIMAT Foundation, Tosu, Japan.
Takayuki HashimotoGlobal Center for Biomedical Science and Engineering, Hokkaido University Faculty of Medicine, Sapporo, Japan.
Hisateru OhbaQST Hospital, National Institutes for Quantum Science and Technology, Chiba, Japan.
Shoji KuboDepartment of Hepato-Biliary-Pancreatic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Kiyoshi HasegawaHepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kazushi MaruoDepartment of Biostatistics, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Hideyuki SakuraiDepartment of Radiation Oncology, University of Tsukuba, Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A prospective study was started in May 2016 to evaluate the efficacy and safety of particle therapy for intrahepatic cholangial carcinoma (ICC). To compare treatment modalities, we also conducted a meta-analysis of literature data and a systematic comparison using registry data. Methods: Patients who received particle therapy for ICC from May 2016 to June 2018 were registered. Nineteen manuscripts (4 particle therapy, 8 3D-CRT, 7 SBRT) were selected for the meta-analysis. Results: A total of 85 cases (proton beam therapy 59, carbon therapy 26) were registered. The median overall survival (OS) of the 85 patients was 22.1 months (95% CI: 12.9-31.3); the 1-, 2-, 3-, and 4-year OS rates were 70.9% (95% CI: 61.1-80.7%), 47.6% (36.8-58.4%), 37.7% (26.7-48.7%), and 22.7% (10.2-35.2%), respectively; and the 1-, 2-, 3-, and 4-year local recurrence rates were 8.2% (1.1-15.3%), 21.6% (9.3-33.9%), 33.4% (16.7-50.1%), and 33.4% (16.7-50.1%), respectively. In the meta-analysis and registry data, the 1-year OS for particle therapy, SBRT and 3D-CRT were 71.8% (95% CI: 64.6-77.8%), 59.2% (53.0-64.9%, Conclusions: Particle therapy achieved a good therapeutic effect for ICC, and a meta-analysis indicated that particle therapy is a better treatment modality than SBRT and 3D-CRT.

Indexed as

Intrahepatic cholangiocarcinomaMeta-analysisParticle therapyRadiotherapySystematic review

Identifiers

PMID40255872
PMCPMC12005709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.